In vitro and in silico studies of potential coronavirus-specific 3C-like protease inhibitors

Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement

In the development of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) drugs, its main protease (Mpro), which is an essential enzyme for viral replication, is a promising target. To date, the Mpro inhibitors, nirmatrelvir and ensitrelvir, have been clinically developed by Pfizer Inc. and Shionogi & Co., Ltd., respectively, as orally administrable drugs to treat coronavirus disease of 2019 (COVID-19). We have also developed several potent inhibitors of SARS-CoV-2 Mpro that include compounds 4, 5, TKB245 (6), and TKB248 (7), which possesses a 4-fluorobenzothiazole ketone moiety as a reactive warhead. In compounds 5 and TKB248 (7) we have also found that replacement of the P1-P2 amide of compounds 4 and TKB245 (6) with the corresponding thioamide improved their pharmacokinetics (PK) profile in mice. Here, we report the design, synthesis and evaluation of SARS-CoV-2 Mpro inhibitors with replacement of a digestible amide bond by surrogates (9-11, 33, and 34) and introduction of fluorine atoms in a metabolically reactive methyl group on the indole moiety (8). As the results, these compounds showed comparable or less potency compared to the corresponding parent compounds, YH-53/5h (2) and 4. These results should provide useful information for further development of Mpro inhibitors.

Molecular docking-assisted investigation of Pd(II) complexes carrying "SNS" pincer-type pyridine-thioether ligand as potential drug candidates against COVID-19

The coronavirus disease 2019 (COVID-19) pandemic has posed a threat to public health throughout the world since the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was discovered in late 2019. Since the beginning of the pandemic, scientists have done a tremendous amount of work in this area. However, among these studies, the investigation of the effect of newly synthesized compounds against coronavirus is rather weak. Examining the newly synthesized compounds with a computer-assisted molecular docking study provides quite an advantage in terms of the estimation and analysis of the biochemical activity and binding affinity of existing synthesized compounds against a biological target in a labor, time, and cost-saving way. In this study, the SNS pincer type 2,6-bis[[(4-methylphenyl)thio]methyl]pyridine ligand(L) (1) and its novel Pd(II) complexes ([Pd(κ²-L)(OAc)₂]·3H₂O (2) and [Pd(κ²-L)Cl₂]·3H₂O (3)) were synthesized and characterized by using FT-IR, UV-Vis, NMR, mass and elemental analysis techniques. The synthesized Pd complexes exhibited a square planar structure. The compounds were found to have non-electrolytic behavior. In the meantime, in silico investigations have defined and justified interaction processes between these molecules and Pd(II) at the atomic level. Furthermore, using molecular docking against target proteins of SARS-CoV-2, the efficiency of the SNS pincer type ligand and its Pd (II) complexes produced was studied and discussed for the first time. The experimental data has been supported and illuminated using computational visual methods and molecular docking, and the findings produced indicate compatibility. The binding energy values of the relevant compounds on the four protein model structures of SARS-CoV-2 (Main Protease, Papain-like protease, RdRp without RNA, and RdRp with RNA) are represented. Compound 2 ([Pd(κ²-L)(OAc)₂]·3H₂O) is the structure that exhibits the highest biochemical activity. According to all of the docking studies, Papain-like protease is the SARS-CoV-2 protein with which the three compounds exhibit mutual interaction. The compound 2 structure, in particular, is the most effective in terms of structural and interaction with the targets, as well as binding orientations.

Immunomodulatory effects of Abelmoschus esculentus water extract through MAPK and NF-κB signaling in RAW 264.7 cells

During the current COVID-19 pandemic, the world is facing a new, highly contagious virus that suppresses innate immunity as one of its early virulence mechanisms. Therefore, finding new methods to enhance innate immunity is a promising strategy to attenuate the effects of this major global health problem. With the aim of characterizing bioactive ingredients as immune-enhancing agents, this study focuses on Abelmoschus esculentus (okra), which has several previously demonstrated bioactivities. Firstly, we investigated the immune-stimulatory effects of okra leaf ethanol extract (OLE) and okra leaf water extract (OLW) on nitric oxide (NO) production in macrophages. OLE significantly decreased nitrite accumulation in LPS-stimulated RAW 264.7 cells, indicating that it potentially inhibited NO production in a concentration-dependent manner. In contrast, OLW significantly enhanced the production of prostaglandin E₂ (PGE₂), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and NO in a dose-dependent manner. OLW also increased the expression levels of NO synthase (iNOS) and cyclooxygenase (COX)-2, potentially explaining the OLW-induced increase in NO and PGE₂ production. In addition, OLW stimulated the phosphorylation of mitogen-activated protein kinases (MAPKs; ERK, p38, and JNK) as well as the activation and subsequent nuclear translocation of nuclear factor κB (NF-κB). This indicated that OLW activates macrophages to secrete PGE₂, TNF-α, IL-1β, and NO, inducing iNOS and COX-2 expression via activation of the NF-κB and MAPK signaling pathways. In conclusion, our results demonstrate that OLW can effectively promote the activation of macrophages, suggesting that OLW may possess potent immunomodulatory effects and should be explored as a potential health-promoting materials to boost the immune system.